Infections caused by Pseudomonas aeruginosa are a significant problem in human healthcare. This bacterial pathogen is the principle agent of sepsis in burn patients;of persistent lung infections and mortality in cystic fibrosis patients;of nosocomial infections in HIV and other immune-suppressed patients;and of the outbreak of deleterious multi-drug resistant infections in hospitals. The long-term goal of this proposal is to provide effective and selective therapies that reduce the incidence and complications of human P. aeruginosa infections. This study proposes this goal can be achieved by drugs that prevent or limit the activation of the MvfR/HAQ pathway, and the development of such anti-infective compounds is the immediate goal of this application. This proposal is based on the hypothesis that MvfR, a P. aeruginosa transcriptional regulator, is a candidate target for anti-infective drugs, as it plays a central role in modulating the expression of many QS-controlled virulence-associated factors;and its activation is mediated by its binding to a specific ligand, which is essential for its function. To identify MvfR-pathway inhibitors, and demonstrate their in vivo anti-infective activity, this study proposes three Specific Aims: 1) to confirm the identity of the MvfR ligand, identify its binding site, and determine its mechanism of action;2) to identify compounds that inhibit the MvfR/HAQ pathway;and 3) to determine the in vivo efficacy and potential feasibility of these inhibitors to limit P. aeruginosa infection in mammals.
These aims will be accomplished via three sets of experiments. First, biochemical, mass spectrometric, and molecular genetic analyses will confirm the identity of the P. aeruginosa MvfR-ligand;define the MvfR ligand binding domain;and determine the pqsA promoter sequence recognized and bound by MvfR and the MvfR-ligand complex. Second, biochemical and mass spectrometric analyses will identify compounds that prevent ligand-mediated MvfR activation by limiting the synthesis and/or binding of its ligand, and that are metabolically stable in P. aeruginosa. Third, each identified inhibitor will be tested in the Drosophila melanogaster, the mouse full-thickness skin thermal injury, and the mouse neonatal respiratory model, to determine their toxicity, their in vivo efficacy to limit P. aeruginosa infection;and their """"""""immunity"""""""" to the development of bacterial resistance. Specific inhibition of a pathway that directly mediates virulence is less likely to generate selective pressure to develop resistance to the inhibitor, than for drugs, including most antibiotics, that reduce bacterial viability. Such targeted inhibitors could significantly enhance the long-term prognosis of burn, cystic fibrosis, and HIV patients. To this end, the results here should enable novel therapies to treat and/or prevent P. aeruginosa-human infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI063433-05
Application #
7796681
Study Section
Bacterial Pathogenesis Study Section (BACP)
Program Officer
Taylor, Christopher E,
Project Start
2006-04-01
Project End
2011-12-31
Budget Start
2010-04-01
Budget End
2011-12-31
Support Year
5
Fiscal Year
2010
Total Cost
$377,071
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Kitao, Tomoe; Lepine, Francois; Babloudi, Seda et al. (2018) Molecular Insights into Function and Competitive Inhibition of Pseudomonas aeruginosa Multiple Virulence Factor Regulator. MBio 9:
Maura, Damien; Ballok, Alicia E; Rahme, Laurence G (2016) Considerations and caveats in anti-virulence drug development. Curr Opin Microbiol 33:41-46
Hazan, Ronen; Que, Yok Ai; Maura, Damien et al. (2016) Auto Poisoning of the Respiratory Chain by a Quorum-Sensing-Regulated Molecule Favors Biofilm Formation and Antibiotic Tolerance. Curr Biol 26:195-206
Hazan, Ronen; Que, Yok-Ai; Maura, Damien et al. (2012) A method for high throughput determination of viable bacteria cell counts in 96-well plates. BMC Microbiol 12:259
Que, Yok-Ai; Hazan, Ronen; Ryan, Colleen M et al. (2011) Production of Pseudomonas aeruginosa Intercellular Small Signaling Molecules in Human Burn Wounds. J Pathog 2011:549302
Kesarwani, Meenu; Hazan, Ronen; He, Jianxin et al. (2011) A quorum sensing regulated small volatile molecule reduces acute virulence and promotes chronic infection phenotypes. PLoS Pathog 7:e1002192
Andronesi, Ovidiu C; Mintzopoulos, Dionyssios; Righi, Valeria et al. (2010) Combined off-resonance imaging and T2 relaxation in the rotating frame for positive contrast MR imaging of infection in a murine burn model. J Magn Reson Imaging 32:1172-83
Righi, Valeria; Apidianakis, Yiorgos; Rahme, Laurence G et al. (2010) Magnetic resonance spectroscopy of live Drosophila melanogaster using magic angle spinning. J Vis Exp :
Righi, Valeria; Apidianakis, Yiorgos; Mintzopoulos, Dionyssios et al. (2010) In vivo high-resolution magic angle spinning magnetic resonance spectroscopy of Drosophila melanogaster at 14.1 T shows trauma in aging and in innate immune-deficiency is linked to reduced insulin signaling. Int J Mol Med 26:175-84
Hazan, Ronen; He, Jianxin; Xiao, Gaoping et al. (2010) Homeostatic interplay between bacterial cell-cell signaling and iron in virulence. PLoS Pathog 6:e1000810

Showing the most recent 10 out of 18 publications